Figure 1 shows the [18F]FPEB binding to mGluR5 in one male and one female mouse from each group (FMR1-KO and control); revealing differences in mGluR5 availability between the groups in multiple brain areas known to be impacted in FXS, based on preclinical and clinical studies. This evidence concerns the gene GRM5 and fragile X syndrome.